Center for Clinical Research on Neurological Diseases, the First Affiliated Hospital, Dalian Medical University, Dalian, 116021, China.
Liaoning Provincial Key Laboratory for Research on the Pathogenic Mechanisms of Neurological Diseases, the First Affiliated Hospital, Dalian Medical University, Dalian, 116021, China.
Neurosci Bull. 2017 Oct;33(5):543-551. doi: 10.1007/s12264-017-0160-z. Epub 2017 Jul 31.
Parkinson's disease (PD) is the second most common age-related neurodegenerative disorder after Alzheimer's disease. To date, the clinical diagnosis of PD is primarily based on the late onset of motor impairments. Unfortunately, at this stage, most of the dopaminergic neurons may have already been lost, leading to the limited clinical benefits of current therapeutics. Therefore, early identification of PD, especially at the prodromal stage, is still a main challenge in the diagnosis and management of this disease. Recently, microRNAs (miRNAs) in cerebrospinal fluid or peripheral blood have been proposed as putative biomarkers to assist in PD diagnosis and therapy. In this review, we systematically summarize the changes of miRNA expression profiles in PD patients, and highlight their putative roles in the diagnosis and treatment of this devastating disease.
帕金森病（PD）是仅次于阿尔茨海默病的第二大与年龄相关的神经退行性疾病。迄今为止，PD 的临床诊断主要基于运动障碍的晚期发作。不幸的是，在这个阶段，大多数多巴胺能神经元可能已经丢失，导致当前治疗方法的临床获益有限。因此，PD 的早期识别，特别是在前驱期，仍然是该疾病诊断和管理中的主要挑战。最近，脑脊液或外周血中的 microRNAs（miRNAs）被提议作为辅助 PD 诊断和治疗的潜在生物标志物。在这篇综述中，我们系统地总结了 PD 患者中 miRNA 表达谱的变化，并强调了它们在诊断和治疗这种破坏性疾病中的潜在作用。
